Journal of Thoracic Imaging:
Smoking-related Lung Disease
Galvin, Jeffrey R. MD* †; Franks, Teri J. MD‡
*Department of Diagnostic Radiology and Internal Medicine, Division of Pulmonary and Critical Care Medicine, University of Maryland School of Medicine, Baltimore, Maryland
†Department of Radiologic Pathology
‡Department of Pulmonary and Mediastinal Pathology, Armed Forces Institute of Pathology, Washington, DC
Reprints: Jeffrey R. Galvin, MD, Department of Radiologic Pathology, Armed Forces Institute of Pathology, 6825 16th Street NW, Washington, DC 20306-6000 (e-mail: firstname.lastname@example.org).
The opinions and assertions contained herein are the expressed views of the authors and are not to be construed as official or reflecting the views of the Departments of the Army or Defense. This is a United States Government work, and as such, is in the public domain in the United States of America.
Abstract: Dyspneic smokers who come to clinical attention demonstrate varying combinations of emphysema, airway inflammation, and fibrosis in addition to the changes of pulmonary Langerhans' cell histiocytosis. There is also growing acceptance of a link between cigarette smoke and alveolar wall fibrosis. Acute eosinophilic pneumonia is a dramatic response to recent-onset smoking seen in a small number of individuals. The interconnected pathways that lead to lung inflammation and fibrosis in cigarette smokers are slowly coming into focus.
Inhalation of cigarette smoke is tacitly accepted as the main cause of chronic obstructive pulmonary disease and is characterized by airflow limitation that is not fully reversible and is commonly progressive.1 Cigarette smoke is a powerful inducer of inflammation that is primarily orchestrated by increased numbers of macrophages that are attracted and retained in the lung.2,3 These macrophages draw additional inflammatory cells into the lung including neutrophils, monocytes, eosinophils, and T-lymphocytes. The result is a destructive cascade of elastolytic compounds and reactive oxidative species that destroy the lung structure resulting in emphysema and obstructive bronchiolitis (Figs. 1, 2). Langerhans' cells, a subtype of dendritic cells, form a rich network on the surface of airways. They increase in number with exposure to the cigarette smoke, accelerating airway inflammation and dysfunction, often resulting in bronchiolocentric stellate nodules and scars.2
Intimately coupled to this destructive inflammatory cascade is a distorted attempt at lung and airway repair, which is observed microscopically, as deposition of the collagen and fibrous tissue.4 Bronchiolar fibrosis is the primary driver of small airway obstruction in chronic obstructive pulmonary disease and is strongly associated with progressive disease.5 This form of fibrosis is associated with the intensity and duration of cigarette smoke exposure.6,7 Alveolar wall fibrosis is also commonly observed in cigarette smokers. A substantial literature documents the association between cigarette smoke and alveolar wall fibrosis4,8–17 and there is increasing recognition of the syndrome of combined pulmonary fibrosis and emphysema that is distinct from idiopathic pulmonary fibrosis.18–21
We have traditionally attempted to subclassify the smoking-related lung injury by the predominant cell type and distribution within the lung parenchyma. The result is a list of legacy terms, some of which have been carried forward over decades, despite substantial changes in our understanding of the underlying pathophysiology.22,23 The list includes:
2. Obstructive bronchiolitis
3. Respiratory bronchiolitis-interstitial lung disease (RB-ILD)
4. Desquamative interstitial pneumonia (DIP)
5. Pulmonary Langerhans' cell histiocytosis (PLCH)
6. Acute eosinophilic pneumonia (AEP).
The above categories, although compelling in their seeming utility, obscure the growing realization that variable combinations of inflammatory cells and fibrosis are commonly identified in most cigarette smokers who come to open lung biopsy. Greater progress in understanding the human response to cigarette smoke may come from investigating what binds these process together rather than drawing lines between them. In the meantime, we have described the diseases according to currently accepted categories while highlighting the overlap between processes where appropriate.
RB AND RB-ILD
In 1974, Niewoehner described the presence of pigmented macrophages in and around the respiratory bronchioles of young smokers and postulated that these macrophages were the precursor of centrilobular emphysema.24 More recent longitudinal imaging studies lend support to the concept that the macrophages of respiratory bronchiolitis (RB) play an important role in alveolar wall destruction.25 The presence of pigmented macrophages in the lung is a highly accurate marker for cigarette smoking with most of the RB patients reporting either current or past cigarette use.7 The macrophages can persist for decades after individuals have stopped smoking.7,26 The majority of patients with RB are asymptomatic, however, as reported by Myers et al27 some patients present with nonspecific symptoms including dyspnea and cough. Most are heavy smokers with restrictive or mixed restrictive/obstructive pulmonary functions that suggest the presence of interstitial lung disease.26 These patients now carry the diagnosis of RB-ILD, a term conceived by Yousem et al.28
RB is a histopathologic lesion. It is the most common form of small airways injury and is seen virtually in all biopsy specimens from cigarette smokers.7 RB is characterized by airway-centered accumulations of macrophages containing finely granular yellow-brown cytoplasmic pigment within distal bronchioles, alveolar ducts, and adjacent alveolar spaces (Fig. 2C). Cytoplasmic pigmentation is variable and correlates with the number of pack-years smoked.7 The macrophages may be accompanied by mild chronic interstitial inflammation (Fig. 2D), and/or mild fibrosis of the airway and peribronchiolar alveolar septa (Fig. 2E). There are no histologic features that separate RB and RB-ILD. RB-ILD, which is rare, is a clinical-radiologic-pathologic diagnosis defined by pulmonary symptoms, abnormal pulmonary functions, abnormal imaging, and a surgical lung biopsy demonstrating RB.7
In a large prospective study, asymptomatic smokers demonstrated upper lobe predominant parenchymal abnormalities including micronodules (27%), areas of ground-glass (21%), emphysema (21%), and bronchial wall thickening (33%).29 Histologic correlation found changes of RB and thickening of alveolar walls with inflammatory cells in areas of ground-glass with bronchioloectasis and peribrochiolar fibrosis in area of micronodularity (Fig. 3).30 Similar results have been found in a more recent study of patients with RB-ILD in which the most common findings included: bronchial wall thickening, centrilobular nodules, areas of ground-glass, and upper lobe predominant centrilobular emphysema (Fig. 3).31 Areas of hypoattenuation were noted in 38% and were most likely related to air trapping. In addition to RB the differential for micronodules in smokers (Fig. 4) encompasses PLCH, bronchiolar fibrosis, and the premalignant lesion of atypical adenomatous hyperplasia. In nonsmokers the differential for centrilobular nodules and focal areas of low attenuation must include subacute hypersensitivity pneumonitis.32 The likelihood of acquiring hypersensitivity pneumonitis is decreased in cigarette smokers for reasons that are not well understood.
Averill Leibow described dyspneic patients with numerous inflammatory cells that expanded the alveolar spaces.23 These cells were originally described as desquamated pneumocytes but are now recognized as alveolar macrophages, the same as those identified in patients with RB and RB-ILD. Given this understanding, there have been calls to change the name to alveolar macrophage pneumonia, however, the use of DIP persists.22 The majority of patients with DIP are cigarette smokers who present with dypnea, cough, and restrictive pulmonary functions. The clinical phenotype and histology are similar to RB-ILD and it is therefore reasonable to view the 2 diseases as a spectrum of injury in cigarette smokers. However, the incidence of smoking is lower in DIP patients (60% to 90% in reported series) although it is nearly universal in RB/RB-ILD.7,33–35 DIP-like reactions have been described in pneumoconioses and drug reactions supporting the need for a category separate from RB/RB-ILD in nonsmokers.22
DIP is characterized by the presence of pigmented macrophages diffusely distributed within alveolar spaces. Although the alveolar walls are variably thickened by diffuse fibrosis and mild infiltrates of chronic inflammatory cells, the alveolar wall architecture is preserved and typically lacks honeycombing. Histologically, the findings in DIP overlap those of RB-ILD and separation of the 2 is based on the distribution of pigmented macrophages. In DIP, macrophages are diffusely distributed throughout the secondary lobule whereas in RB-ILD they are bronchiolocentric. However, macrophage distribution can vary considerably from 1 alveolus to the next and 1 histologic section to another making the separation of DIP from RB-ILD difficult and often quite arbitrary. Assessment of macrophage distribution can be limited by sample size and site biopsied (Fig. 5).
Homogenous or patchy increase in lung attenuation or ground-glass is reported as the most common finding in patients with DIP in most series.33–37 The mid and lower lung zones are predominantly involved (Fig. 5) and there is a predilection for the involvement of the periphery of the lung.34
CIGARETTE SMOKE AND PULMONARY FIBROSIS
A more contentious issue relates to the acceptance of fibrosis as a part of the expected array findings in cigarette smokers. Niewoehners's seminal description of RB did not include alveolar wall fibrosis, however, the mean age of his subjects was 25 years.24 Subsequent studies have shown a strong association between bronchiolar fibrosis and the duration of cigarette smoke exposure in older adults.6,7 Yousem38 recently described 9 patients with RB and diffuse alveolar wall fibrosis that fits the pattern of nonspecific interstitial pneumonia (NSIP).
In Liebow's original description of DIP, fibrosis of alveolar walls was observed to a “modest degree” and there has been reluctance to accept more severe fibrosis as a part of the expected range of findings.23 The current consensus classification does not include fibrosis in its histologic description even though most of the series demonstrate histologic or radiologic evidence of fibrosis in greater than 50% of cases.33–36,39 In some cases the fibrosis is relatively uniform and below the resolution of chest computed tomography (Fig. 6). However, in our experience, well-formed cystic spaces, seen on high-resolution computed tomography, that follow the distribution of smoking-related emphysema are common in dyspneic smokers who come to open lung biopsy (unpublished data) (Fig. 7). Those cystic spaces correlate with fibrotic walls that surround simplified areas of emphysema. The spaces are commonly filled with smoker's macrophages. The fibrosis fits the definition of NSIP.21 The well-outlined cystic spaces suggest the possibility of usual interstitial pneumonia, however, the distribution of cysts in this subset of cigarette smokers follows the distribution of typical smoking-related emphysema. The holes are larger and more prominent in the upper lung fields, which is distinct from usual interstitial pneumonitis in which the cysts are strikingly peripheral with a lower lobe predominance. Patients who present with combined emphysema and fibrotic NSIP are severely dyspneic with relatively normal spirometry and markedly reduced diffusing capacity of the lung of carbonmonoxide (unpublished data) fit the increasingly recognized syndrome of combined pulmonary fibrosis and emphysema.18–21,39 As previously mentioned, there is long standing support for the concept of smoking-related fibrosis other than usual interstitial pneumonitis.4,8,9,11,12,14,16,17,38 Hansell and Nicholson speculate that some smokers with the NSIP pattern of fibrosis may represent the late stage of fibrotic DIP in which the macrophages have been cleared from the alveoli.39
PLCH is a part of spectrum of disease now collectively known as Langerhans' cell histiocytosis. The classification has been simplified and is based on the presence of single or multiorgan involvement.40,41 In the majority of patients PLCH is isolated to the lungs with only 5% to 15% demonstrating multiorgan involvement including bone lesions, skin lesions, and diabetes insipidus.41 Patients most commonly present with dypnea and cough, although up to 25% are asymptomatic at the time of disease discovery. PLCH primarily affects individuals in the 3rd to 5th decade of life, however, the relative frequency of males and females affected remains unsettled with studies demonstrating a slight predominance of either sex.42,43 It is an uncommon disease found in approximately 3.4% of patients undergoing open lung biopsy for chronic interstitial lung disease.44 The pathogenesis remains unknown, however, 90% or more of PLCH patients are cigarette smokers.43,45 Pulmonary hypertension is more prominent in advanced PLCH than in other chronic lung diseases owing to direct intrinsic pulmonary vascular involvement.46
PLCH is characterized by discrete bronchiolocentric, stellate interstitial nodules (Fig. 8C) which in the early stage are cellular and comprised of Langerhans' cells admixed with variable numbers of lymphocytes, fibroblasts, eosinophils, neutrophils, plasma cells, and pigmented macrophages (Fig. 8C). Langerhans' cells display characteristic deeply grooved nuclei and are immunoreactive with CD1a and S-100. Over time, early cellular nodules are replaced in a centripetal fashion by fibrous tissue to form cellular and fibrotic nodules and, in the late stage, entirely fibrotic bronchiolocentric stellate scars surrounded by distorted and enlarged air spaces.43,47
The chest radiograph is usually abnormal demonstrating a mixture of reticular and micronodular opacities predominantly in the mid and upper lung zones (Fig. 8A).48 Lung volumes are normal or increased.
High-resolution computed tomography mirrors the typical upper lobe predominance noted on chest radiography but resolves the reticular change into a combination of nodules and cysts with varying wall thickness (Fig. 8B).49 The combination of irregularly shaped cysts and peribronchiolar nodules that predominate in the upper portion of the chest obviates the need for lung biopsy in the appropriate clinical circumstance.41 Progression from a nodular pattern to a predominance of thin-walled cysts is typical (Fig. 9).50 The later stages of the disease are associated with significant emphysema either related to the stellate scaring of PLCH and/or typical smoking-related emphysema (Fig. 10).
Ground-glass attenuation in patients with PLCH correlates with the presence of RB-DIP-like changes highlighting the concept that PLCH, RB, and DIP form a spectrum of injury in cigarette smokers.51
AEP was described by Allen et al52 and is characterized by an acute febrile illness, hypoxemia, diffuse pulmonary infiltrates, and increased numbers of eosinophils on bronchoalveolar lavage. Blood eosinophil counts may be normal. Patients usually present with respiratory failure and require intubation. Those treated with corticosteroids respond rapidly; usually within days. Spontaneous recovery has been reported.53 In most cases a causative agent is not identified, however, recent-onset cigarette smoking has been convincingly linked with AEP.54–58 Repeat exposure to cigarette smoke has consistently resulted in the recurrence of the symptoms, laboratory changes, and physical findings confirming the diagnosis.58,59 In a recent report, 18 military personnel deployed in Iraq developed AEP.57 All of the patients were cigarette smokers of which 78% were recent onset. All 6 of the patients who underwent bronchoalveolar lavage demonstrated marked eosinophilia.
AEP may be mistaken for other diseases including severe community-acquired pneumonia and acute respiratory distress syndrome (ARDS). Distinguishing AEP from ARDS is crucial given the differing responses to corticosteroids. Those with AEP respond rapidly to steroids whereas those with ARDS do not benefit and have a poor prognosis.
AEP shows findings of diffuse alveolar damage coupled with interstitial and alveolar infiltrates of eosinophils. Diffuse alveolar damage is a pattern of acute lung injury characterized in the acute phase by hyaline membranes, interstitial and intra-alveolar edema, patchy type ll pneumocyte hyperplasia, and microthrombi (Fig. 11C). The acute phase forms a continuum with the organizing phase in which proliferation of interstitial fibroblasts, organizing alveolar exudates, and prominent type ll pneumocyte hyperplasia are the histologic hallmarks.
On chest radiography those with AEP demonstrate bilateral reticular opacities, commonly with Kerley B (septal) lines. There is rapid progression over hours to days with increasing bilateral areas of patchy or diffuse consolidation. Computed tomography scans demonstrate bilateral areas of ground-glass, consolidation and septal thickening (Fig. 11).54 Unilateral or bilateral pleural effusions are present at some point during the course of the illness in all patients. The radiologic findings are similar to those of pulmonary edema although the heart size is usually normal. The radiologic differential includes ARDS, although septal lines are less common, pulmonary hemorrhage and infection.
INTERRELATIONSHIP OF SMOKING-RELATED LUNG DISEASES
Pigmented macrophages are found in and around the airways of all cigarette smokes. Those same macrophages may have a more extensive distribution and those patients currently carry the label of DIP. Dyspneic smokers who come to clinical attention demonstrate varying combinations of emphysema, airway inflammation/fibrosis, and alveolar wall fibrosis in addition to changes of PLCH. AEP is a dramatic response to recent-onset smoking seen in a small number of individuals. The interconnected pathways that lead to lung inflammation and fibrosis in cigarette smokers are slowly coming into focus (Fig. 1).2,3
1. Pauwels RA, Buist AS, Calverley PM, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med. 2001;163:1256–1276.
2. Barnes PJ, Shapiro SD, Pauwels RA. Chronic obstructive pulmonary disease: molecular and cellular mechanisms. Eur Respir J. 2003;22:672–688.
3. Spurzem JR, Rennard SI. Pathogenesis of COPD. Semin Respir Crit Care Med. 2005;26:142–153.
4. Niewoehner DE, Hoidal JR. Lung fibrosis and emphysema: divergent responses to a common injury? Science. 1982;217:359–360.
5. Hogg JC, Chu F, Utokaparch S, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med. 2004;350:2645–2653.
6. Adesina AM, Vallyathan V, McQuillen EN, et al. Bronchiolar inflammation and fibrosis associated with smoking. A morphologic cross-sectional population analysis. Am Rev Respir Dis. 1991;143:144–149.
7. Fraig M, Shreesha U, Savici D, et al. Respiratory bronchiolitis: a clinicopathologic study in current smokers, ex-smokers, and never-smokers. Am J Surg Pathol. 2002;26:647–653.
8. Auerbach O, Garfinkel L, Hammond EC. Relation of smoking and age to findings in lung parenchyma: a microscopic study. Chest. 1974;65:29–35.
9. Auerbach O, Stout AP, Hammond EC, et al. Smoking habits and age in relation to pulmonary changes. Rupture of alveolar septums, fibrosis and thickening of walls of small arteries and arterioles. N Engl J Med. 1963;269:1045–1054.
10. Frasca JM, Auerbach O, Carter HW, et al. Morphologic alterations induced by short-term cigarette smoking. Am J Pathol. 1983;111:11–20.
11. Hammond EC, Auerbach O, Kirman D, et al. Effects of cigarette smoking on dogs. Arch Environ Health. 1970;21:740–753.
12. Lang MR, Fiaux GW, Gillooly M, et al. Collagen content of alveolar wall tissue in emphysematous and non-emphysematous lungs. Thorax. 1994;49:319–326.
13. Martin-Mosquero C, Peces-Barba G, Rubio ML, et al. Increased collagen deposition correlated with lung destruction in human emphysema. Histol Histopathol. 2006;21:823–828.
14. Nagai A, Thurlbeck WM. Scanning electron microscopic observations of emphysema in humans. A descriptive study. Am Rev Respir Dis. 1991;144:901–908.
15. Snider GL, Lucey EC, Faris B, et al. Cadmium-chloride-induced air-space enlargement with interstitial pulmonary fibrosis is not associated with destruction of lung elastin. Implications for the pathogenesis of human emphysema. Am Rev Respir Dis. 1988;137:918–923.
16. Weiss W. Cigarette smoking and diffuse pulmonary fibrosis. Am Rev Respir Dis. 1969;99:67–72.
17. Weiss W. Smoking and pulmonary fibrosis. J Occup Med. 1988;30:33–39.
18. Cottin V, Cordier JF. Combined pulmonary fibrosis and emphysema: an experimental and clinically relevant phenotype. Am J Respir Crit Care Med. 2005;172:1605; author reply 1605–1606.
19. Cottin V, Nunes H, Brillet PY, et al. Combined pulmonary fibrosis and emphysema: a distinct underrecognised entity. Eur Respir J. 2005;26:586–593.
20. Grubstein A, Bendayan D, Schactman I, et al. Concomitant upper-lobe bullous emphysema, lower-lobe interstitial fibrosis and pulmonary hypertension in heavy smokers: report of eight cases and review of the literature. Respir Med. 2005;99:948–954.
21. Tonelli M, Stern EJ, Glenny RW. HRCT evident fibrosis in isolated pulmonary emphysema. J Comput Assist Tomogr. 1997;21:322–323.
22. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med. 2002;165:277–304.
23. Liebow AA, Steer A, Billingsley JG. Desquamative Interstitial Pneumonia. Am J Med. 1965;39:369–404.
24. Niewoehner DE, Kleinerman J, Rice DB. Pathologic changes in the peripheral airways of young cigarette smokers. N Engl J Med. 1974;291:755–758.
25. Remy-Jardin M, Edme JL, Boulenguez C, et al. Longitudinal follow-up study of smoker's lung with thin-section CT in correlation with pulmonary function tests. Radiology. 2002;222:261–270.
26. Ryu JH, Myers JL, Capizzi SA, et al. Desquamative interstitial pneumonia and respiratory bronchiolitis-associated interstitial lung disease. Chest. 2005;127:178–184.
27. Myers JL, Veal CF Jr, Shin MS, et al. Respiratory bronchiolitis causing interstitial lung disease. A clinicopathologic study of six cases. Am Rev Respir Dis. 1987;135:880–884.
28. Yousem SA, Colby TV, Gaensler EA. Respiratory bronchiolitis-associated interstitial lung disease and its relationship to desquamative interstitial pneumonia. Mayo Clin Proc. 1989;64:1373–1380.
29. Remy-Jardin M, Remy J, Boulenguez C, et al. Morphologic effects of cigarette smoking on airways and pulmonary parenchyma in healthy adult volunteers: CT evaluation and correlation with pulmonary function tests. Radiology. 1993;186:107–115.
30. Remy-Jardin M, Remy J, Gosselin B, et al. Lung parenchymal changes secondary to cigarette smoking: pathologic-CT correlations. Radiology. 1993;186:643–651.
31. Park JS, Brown KK, Tuder RM, et al. Respiratory bronchiolitis-associated interstitial lung disease: radiologic features with clinical and pathologic correlation. J Comput Assist Tomogr. 2002;26:13–20.
32. Warren CP. Extrinsic allergic alveolitis: a disease commoner in non-smokers. Thorax. 1977;32:567–569.
33. Craig PJ, Wells AU, Doffman S, et al. Desquamative interstitial pneumonia, respiratory bronchiolitis and their relationship to smoking. Histopathology. 2004;45:275–282.
34. Hartman TE, Primack SL, Swensen SJ, et al. Desquamative interstitial pneumonia: thin-section CT findings in 22 patients. Radiology. 1993;187:787–790.
35. Heyneman LE, Ward S, Lynch DA, et al. Respiratory bronchiolitis, respiratory bronchiolitis-associated interstitial lung disease, and desquamative interstitial pneumonia: different entities or part of the spectrum of the same disease process? AJR Am J Roentgenol. 1999;173:1617–1622.
36. Akira M, Yamamoto S, Hara H, et al. Serial computed tomographic evaluation in desquamative interstitial pneumonia. Thorax. 1997;52:333–337.
37. Hartman TE, Primack SL, Kang EY, et al. Disease progression in usual interstitial pneumonia compared with desquamative interstitial pneumonia. Assessment with serial CT. Chest. 1996;110:378–382.
38. Yousem SA. Respiratory bronchiolitis-associated interstitial lung disease with fibrosis is a lesion distinct from fibrotic nonspecific interstitial pneumonia: a proposal. Mod Pathol. 2006;19:1474–1479.
39. Hansell DM, Nicholson AG. Smoking-related diffuse parenchymal lung disease: HRCT-pathologic correlation. Semin Respir Crit Care Med. 2003;24:377–392.
40. Howarth DM, Gilchrist GS, Mullan BP, et al. Langerhans cell histiocytosis: diagnosis, natural history, management, and outcome. Cancer. 1999;85:2278–2290.
41. Vassallo R, Ryu JH, Colby TV, et al. Pulmonary Langerhans'-cell histiocytosis. N Engl J Med. 2000;342:1969–1978.
42. Basset F, Corrin B, Spencer H, et al. Pulmonary histiocytosis X. Am Rev Respir Dis. 1978;118:811–820.
43. Colby TV, Lombard C. Histiocytosis X in the lung. Hum Pathol. 1983;14:847–856.
44. Gaensler EA, Carrington CB. Open biopsy for chronic diffuse infiltrative lung disease: clinical, roentgenographic, and physiological correlations in 502 patients. Ann Thorac Surg. 1980;30:411–426.
45. Travis WD, Borok Z, Roum JH, et al. Pulmonary Langerhans cell granulomatosis (histiocytosis X). A clinicopathologic study of 48 cases. Am J Surg Pathol. 1993;17:971–986.
46. Fartoukh M, Humbert M, Capron F, et al. Severe pulmonary hypertension in histiocytosis X. Am J Respir Crit Care Med. 2000;161:216–223.
47. Caminati A, Harari S. Smoking-related interstitial pneumonias and pulmonary Langerhans cell histiocytosis. Proc Am Thorac Soc. 2006;3:299–306.
48. Lacronique J, Roth C, Battesti JP, et al. Chest radiological features of pulmonary histiocytosis X: a report based on 50 adult cases. Thorax. 1982;37:104–109.
49. Brauner MW, Grenier P, Mouelhi MM, et al. Pulmonary histiocytosis X: evaluation with high-resolution CT. Radiology. 1989;172:255–258.
50. Brauner MW, Grenier P, Tijani K, et al. Pulmonary Langerhans cell histiocytosis: evolution of lesions on CT scans. Radiology. 1997;204:497–502.
51. Vassallo R, Jensen EA, Colby TV, et al. The overlap between respiratory bronchiolitis and desquamative interstitial pneumonia in pulmonary Langerhans cell histiocytosis: high-resolution CT, histologic, and functional correlations. Chest. 2003;124:1199–1205.
52. Allen JN, Pacht ER, Gadek JE, et al. Acute eosinophilic pneumonia as a reversible cause of noninfectious respiratory failure. N Engl J Med. 1989;321:569–574.
53. Philit F, Etienne-Mastroianni B, Parrot A, et al. Idiopathic acute eosinophilic pneumonia: a study of 22 patients. Am J Respir Crit Care Med. 2002;166:1235–1239.
54. King MA, Pope-Harman AL, Allen JN, et al. Acute eosinophilic pneumonia: radiologic and clinical features. Radiology. 1997;203:715–719.
55. Shintani H, Fujimura M, Ishiura Y, et al. A case of cigarette smoking-induced acute eosinophilic pneumonia showing tolerance. Chest. 2000;117:277–279.
56. Shiota Y, Kawai T, Matsumoto H, et al. Acute eosinophilic pneumonia following cigarette smoking. Intern Med. 2000;39:830–833.
57. Shorr AF, Scoville SL, Cersovsky SB, et al. Acute eosinophilic pneumonia among US Military personnel deployed in or near Iraq. JAMA. 2004;292:2997–3005.
58. Uchiyama H, Suda T, Nakamura Y, et al. Alterations in smoking habits are associated with acute eosinophilic pneumonia. Chest. 2008;133:1174–1180.
59. Shintani H, Fujimura M, Yasui M, et al. Acute eosinophilic pneumonia caused by cigarette smoking. Intern Med. 2000;39:66–68.
cigarette smoke; macrophage; respiratory bronchiolitis; desquamative interstitial pneumonia; fibrosis; Langerhans' cell; acute eosinophilic pneumonia; emphysema
© 2009 Lippincott Williams & Wilkins, Inc.
What does "Remember me" mean?
By checking this box, you'll stay logged in until you logout. You'll get easier access to your articles, collections,
media, and all your other content, even if you close your browser or shut down your
To protect your most sensitive data and activities (like changing your password),
we'll ask you to re-enter your password when you access these services.
What if I'm on a computer that I share with others?
If you're using a public computer or you share this computer with others, we recommend
that you uncheck the "Remember me" box.
Highlight selected keywords in the article text.
Data is temporarily unavailable. Please try again soon.
Readers Of this Article Also Read